Edition:
United States

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

15.45USD
3:59pm EST
Change (% chg)

$-0.10 (-0.64%)
Prev Close
$15.55
Open
$15.50
Day's High
$16.05
Day's Low
$15.40
Volume
91,514
Avg. Vol
239,298
52-wk High
$22.70
52-wk Low
$4.05

Latest Key Developments (Source: Significant Developments)

Abeona Q3 loss per share $0.13
Wednesday, 15 Nov 2017 08:25am EST 

Nov 15 (Reuters) - Abeona Therapeutics Inc :Abeona reports third quarter 2017 financial results and recent business highlights.Q3 loss per share $0.13.Q3 revenue $219,000 versus I/B/E/S view $220,000.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.  Full Article

Abeona Therapeutics announces public offering of common stock
Monday, 16 Oct 2017 04:01pm EDT 

Oct 17 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics announces public offering of common stock.  Full Article

Abeona Therapeutics to receive $13.85 mln of grants for development of Sanfilippo gene therapy programs​
Monday, 16 Oct 2017 08:26am EDT 

Oct 16 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics Inc - ‍nine global foundations collaborate to grant $13.85 million for continued advancement of lead Sanfilippo gene therapy programs​.  Full Article

Abeona Therapeutics enrolls first two patients in phase 1/2 clinical trial in MPS IIIA
Wednesday, 11 Oct 2017 08:19am EDT 

Oct 11 (Reuters) - Abeona Therapeutics Inc : :Abeona Therapeutics enrolls first two patients in pivotal expansion of phase 1/2 clinical trial in MPS IIIA.Says to ‍report additional clinical data in ABO-102 global trial later this year​.  Full Article

Abeona Therapeutics and Brammer Bio announce collaboration for commercial translation of ABO-102
Thursday, 28 Sep 2017 08:32am EDT 

Sept 28 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics and Brammer Bio announce collaboration for commercial translation of ABO-102.Abeona Therapeutics Inc - ‍strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation​.  Full Article

Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101
Tuesday, 29 Aug 2017 09:05am EDT 

Aug 29 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101 autologous cell therapy in Epidermolysis Bullosa.Abeona Therapeutics Inc - company continues to engage FDA on final phase 3 clinical trial design, planned to commence early 2018.  Full Article

Abeona Therapeutics expands gene therapy clinical trials in Sanfilippo Syndrome Type A
Wednesday, 16 Aug 2017 09:25am EDT 

Aug 16 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics announces pivotal expansion of ABO-102 gene therapy clinical trials in Sanfilippo Syndrome Type A.Abeona Therapeutics Inc - ‍planned expansion will enroll an additional eight to ten mps IIIA subjects​.Abeona Therapeutics Inc - ‍total enrollment of fourteen to sixteen subjects to be completed by 1Q2018​.  Full Article

Abeona Therapeutics receives guidance from FDA
Tuesday, 18 Jul 2017 08:05am EDT 

July 18 (Reuters) - Abeona Therapeutics Inc ::Abeona Therapeutics receives guidance from FDA to commence pivotal phase 3 for EB-101 gene therapy for patients with epidermolysis bullosa.Abeona Therapeutics Inc - ‍pivotal phase 3 clinical trial is planned to commence in early 2018​.Says pivotal phase 3 clinical trial is planned to commence in early 2018.Abeona Therapeutics Inc - ‍continues to engage FDA on final phase 3 clinical trial design, planned to commence early 2018​.Abeona Therapeutics Inc - continues to engage FDA on final phase 3 clinical trial design, planned to commence early 2018.  Full Article

Abeona Therapeutics receives FDA orphan drug designation for ABO-201 juvenile Batten disease gene therapy program
Thursday, 29 Jun 2017 08:15am EDT 

June 29 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics receives FDA orphan drug designation for ABO-201 juvenile Batten disease gene therapy program.Abeona Therapeutics Inc - Look forward to initiating human clinical trials later this year for ABO-201 program​.  Full Article

Abeona gets orphan drug status for genetic skin disorder treatment
Thursday, 25 May 2017 08:05am EDT 

May 25 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics receives FDA orphan drug designation for EB-101 gene therapy product for patients with epidermolysis bullosa.  Full Article

BRIEF-Abeona Q3 loss per share $0.13

* Abeona reports third quarter 2017 financial results and recent business highlights